cancer

How Gilead finally spent its money
How Gilead finally spent its money
BioPharma Dive
Gilead Sciences
cancer
oncology
Flag link:
Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Seeking Alpha
AstraZeneca
Fusion Pharmaceuticals
radiopharmaceuticals
cancer
Flag link:
Patrick Soon-Shiong steps down as CEO of NantKwest, a linchpin of his 'Cancer Moonshot'
Patrick Soon-Shiong steps down as CEO of NantKwest, a linchpin of his 'Cancer Moonshot'
Endpoints
Patrick Soon-Shiong
NantKwest
cancer moonshot
cancer
biotech
Flag link:
What can a biotech entrepreneur and a top scientist come up with on a couple of shared flights? Well...
What can a biotech entrepreneur and a top scientist come up with on a couple of shared flights? Well...
Endpoints
Scorpion
cancer
small molecule drugs
precision medicine
Flag link:
David Hung’s Nuvation Bio seals merger with blank check firm Panacea
David Hung’s Nuvation Bio seals merger with blank check firm Panacea
Pharmaforum
Nuvation Bio
David Hung
cancer
Panacea
SPAC
Flag link:
MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies
MD Anderson establishes new $50M+ biotech fund to choose the next promising cancer therapies
Endpoints
MD Anderson
biotech
funding
cancer
oncology
Flag link:
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
Xconomy
SQZ Biotech
cancer
oncology
cell therapy
IPOs
Roche
Flag link:
You've met Moderna, BioNTech and Curevac. Now meet Kernal Bio, the startup working on mRNA 2.0
You've met Moderna, BioNTech and Curevac. Now meet Kernal Bio, the startup working on mRNA 2.0
Fierce Biotech
MRNA
Moderna Therapeutics
BioNTech
CureVac
Kernal Bio
cancer
COVID-19
Flag link:
J&J moving to settle 1,000 talc lawsuits for more than $100M: Bloomberg
J&J moving to settle 1,000 talc lawsuits for more than $100M: Bloomberg
Fierce Pharma
JNJ
lawsuits
cancer
Flag link:
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Genentech pays $200M for Vaccibody's phase 1 cancer vaccine
Fierce Biotech
Genentech
Vaccibody
cancer
vaccines
Roche
cancer vaccines
Flag link:
Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
Endpoints
Pfizer
China
CStone
cancer
Flag link:
Blank check company merger creates cancer specialist Vincera
Blank check company merger creates cancer specialist Vincera
Pharmaforum
SPAC
Vincera
LifeSci Acquisition
oncology
cancer
Bayer
Flag link:
Agios helps identify genes that allow cancer to escape the immune system
Agios helps identify genes that allow cancer to escape the immune system
Fierce Biotech
CRISPR
cancer
Agios Pharmaceuticals
immuno-oncology
Flag link:
Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail
Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail
Motley Fool
M&A
diagnostics
cancer diagnostics
cancer
oncology
Illumina
Grail
Flag link:
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Merck to acquire $1bn equity stake in Seattle Genetics; announces two oncology collaborations
Biopharma Reporter
Merck
Seattle Genetics
cancer
oncology
ADCs
Tukysa
ladiratuzumab vedotin
Flag link:
Esmo 2020 preview – late-breaking immunotherapy
Esmo 2020 preview – late-breaking immunotherapy
EP Vantage
ESMO
immunotherapy
Big Pharma
Merck
Bristol-Meyers Squibb
cancer
Immunomedics
Roche
Flag link:
Gilead to buy cancer drugmaker Immunomedics for $21B
Gilead to buy cancer drugmaker Immunomedics for $21B
BioPharma Dive
Gilead Sciences
M&A
cancer
Immunomedics
Flag link:
Jazz inks Redx pact to secure 2 targeted cancer therapies
Jazz inks Redx pact to secure 2 targeted cancer therapies
Fierce Biotech
Jazz Pharmaceuticals
Redx
cancer
targeted therapies
Flag link:
Oncology biotech Prelude guns for $100M IPO
Oncology biotech Prelude guns for $100M IPO
Fierce Biotech
Prelude Therapeutics
IPOs
cancer
Flag link:
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
Xconomy
Blueprint Medicines
FDA
Gavreto
pralsetinib
cancer
RET
non-small cell lung cancer
Flag link:

Pages